Silence Therapeutics plc: Silence Therapeutics Reports Fourth Quarter and Full Year 2021 Results
Positive SLN360 data to be presented in late breaker at the American College of Cardiology (ACC) Annual Meeting on April 3, 2022 SLN124 phase 1 study in thalassemia now fully enrolled; on-track for
Source: finanznachrichten.de